Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction☆
References (27)
The Cardiac Arrhythmia Pilot Study
Am J Cardiol
(1986)- et al.
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basal Antiarrhythmic Study of Infarct Survival (BASIS)
J Am Coll Cardiol
(1990) - et al.
Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study
J Am Coll Cardiol
(1992) - et al.
Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction
Am J Cardiol
(1987) - et al.
Prospective, double-blind, placebo-controlled trial of low dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy
Am Heart J
(1991) - et al.
Effect of propranolol in patients with myocardial infarction and ventricular arrhythmias
J Am Coll Cardiol
(1986) - et al.
Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure
J Am Coll Cardiol
(1990) - et al.
Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction
J Am Coll Cardiol
(1987) - et al.
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled
J Am Coll Cardiol
(1991) - et al.
Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy
J Am Coll Cardiol
(1990)
A general overview of amiodarone toxicity: its prevention, detection and management
Prog Cardiovasc Dis
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction
Circulation
Effect of antiarrhythmic drugs on mortality after myocardial infarction
Am J Cardiol
Cited by (78)
The “Bayés Spirit” as a guide for new generations: How to combine one's personal life and friendships with science and profession
2023, Journal of ElectrocardiologyChronic Amiodarone Use and the Risk of Cancer: A Systematic Review and Meta-analysis
2021, CJC OpenCitation Excerpt :The authors of 10 studies responded, and the author of 1 trial19 provided unpublished cancer data, which we included in the analyses. Four authors who responded reported that they did not have access to the relevant data if it existed,20-23 and 6 authors responded that they did not collect data on cancer outcomes.24-29 Only 1 trial was at a low risk of bias in all domains (Fig. 2).17
Substrates and potential therapeutics of ventricular arrhythmias in heart failure
2018, European Journal of PharmacologyCitation Excerpt :Amiodarone is a major antiarrhythmic drug in HF (Massie et al., 1996; Nul et al., 1997; Singh et al., 1995) when patients with HF are intolerant of β-adrenergic blockers. Clinical trials in patients with HF demonstrated that amiodarone significantly suppresses ventricular arrhythmias, and reduces mortality and sudden cardiac death without any adverse effects (Amiodarone trials Meta-analysis investigators, 1997; Ceremuzynski et al., 1992; Lo and Hsia, 2008; Navarro-Lopez et al., 1993; Santangeli et al., 2017). The therapeutic effect of amiodarone on ventricular arrhythmias in HF might be dependent on its multiple pharmacological actions, including the blockage of cardiac sodium, potassium, and calcium channels as well as sympatholytic effects (Ellison et al., 2003).
Ventricular Arrhythmias in Heart Failure Patients
2008, Cardiology ClinicsCitation Excerpt :Amiodarone does not appear to have any adverse effect on survival or heart failure. In the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, amiodarone had no significant impact on the incidence of SCD or on total mortality [96]; however, multiple smaller studies have shown significant mortality benefits and SCD reduction with the use of this drug [97–99]. Perhaps the largest of the amiodarone studies are the European Myocardial Infarct Amiodarone Trial and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial, which focused on patients who had ischemic heart disease and prior myocardial infarction.
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
2008, American Heart JournalCitation Excerpt :Among surviving patients who received amiodarone during days 17 to 45, the risk of all-cause and cardiovascular mortality during the follow-up period of 46 to 198 days was not significant. A total of 15 randomized clinical trials have evaluated the efficacy of amiodarone in reducing arrhythmias and all-cause or cardiovascular death.5-10,12,15-21 The 2 largest post-MI studies, EMIAT and CAMIAT, included 1486 and 1202 patients, respectively.
- ☆
This study was supported in part by a research grant (1988–1990) from the Ramon Areces Foundation, Madrid, Spain.
- ∗
A list of the Spanish Study on Sudden Death (SSSD) investigators and participating institutions appears in the Appendix.